Please ensure Javascript is enabled for purposes of website accessibility

Legend Biotech Makes Plans to IPO With Backing From Johnson & Johnson

By Brian Orelli, PhD – May 14, 2020 at 3:16PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The startup aims to take on bluebird bio and Bristol Myers Squibb with its CAR-T therapy targeting BCMA for multiple myeloma.

Legend Biotech is looking to raise $100 million in an initial public offering. The biotech, which hopes to be listed on the Nasdaq under the ticker LEGN, is still early in the IPO process and hasn't established a price range for the shares it plans to sell.

Legend's lead molecule, LCAR-B38M/JNJ-4528, is a chimeric antigen T-cell (CAR-T) therapy targeting B cell maturation antigen (BCMA) for patients with multiple myeloma.

That's the same type of therapy, targeting the same antigen for the same disease, as idecabtagene vicleucel (ide-cel), which bluebird bio (BLUE 11.05%) and Bristol Myers Squibb (BMY -0.86%) are developing in partnership.

LCAR-B38M/JNJ-4528 has two names because Legend licensed 30% of the rights to the drug to Johnson & Johnson's (JNJ -0.71%) Janssen division for $350 million up front plus milestone payments. So far, Johnson & Johnson has paid $110 million to Legend for meeting four milestones, and it's still eligible for $125 million if it achieves manufacturing milestones, plus an additional $1.115 billion for meeting future development, regulatory, and sales milestones.

Paper with the definition of an IPO with a pen highlighting initial public offering

Image source: Getty Images.

Johnson & Johnson is still enrolling patients in a phase 3 clinical trial for LCAR-B38M/JNJ-4528, which puts the drug behind are behind ide-cel. But this week, Bluebird and Bristol Myers Squibb and received a refuse-to-file letter from the Food and Drug Administration in response to their new biologics license application, which will allow Legend and Johnson & Johnson to catch up a little.

Of course, in the long term, this competition will come down to efficacy and safety. Legend thinks its CAR-T design, which contains two binding domains for BCMA, will help its therapy work better than traditional CAR-T therapies that only bind a single domain.

Beyond LCAR-B38M/JNJ-4528, Legend has quite a few wholly-owned pipeline candidates, although they're all in early-stage development.

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Bluebird Bio and Bristol Myers Squibb. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$163.36 (-0.71%) $-1.17
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
BMY
$71.09 (-0.86%) $0.62
bluebird bio, Inc. Stock Quote
bluebird bio, Inc.
BLUE
$6.33 (11.05%) $0.63

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.